ONC.US BeOne Medicines AG

Healthcare Biotechnology USA Stocks
445.83 USD
Close of Nov 16, 2026
253.95 424.73
Market cap
USD 47.0B
P/E
52.7x
P/B
8.17x
ROE
19.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ONC.US undervalued?

Graham number

The Graham number of BeOne Medicines AG cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BeOne Medicines AG fundamental analysis

No fundamental analysis for BeOne Medicines AG yet.

BeOne Medicines AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult…

Full company profile